HCB101, a novel Fc-based anti-SIRPα-CD47 fusion protein, has received orphan drug designation (ODD) from the FDA for the ...

HER2-positive gastric cancer accounts for a substantial proportion of advanced cases and has long been treated with HER2-targeted therapies. While trastuzumab deruxtecan has shown superior activity ...

DPTX3186, a first-in-class beta-catenin condensate modulator, received Orphan Drug Designation and Fast Track Designation from FDAClinical entry ...

Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability–High Advanced Gastric or Esophagogastric Junction Cancer Patients age 20 years and ...

A next-generation antibody–drug conjugate has transformed treatment for HER2-positive gastric cancer, yet many patients fail to benefit or relapse ...

As previously presented at the 2025 European Society for Medical Oncology (ESMO) Annual Congress, the combination ...

In patients with advanced Claudin-18 isoform 2 (CLDN18.2) -positive gastric or gastroesophageal junction cancers, satricabtagene autoleucel (satri-cel) chimeric antigen receptor (CAR) T-cell therapy ...

In a phase III trial, a chemotherapy regimen of fluorouracil, oxaliplatin, and docetaxel (TFOX) improved survival outcomes over standard FOLFOX for patients with advanced HER2-negative gastric cancer.

PD-1 inhibitors are equitably accessed across racial groups, with no significant differences in treatment patterns observed. Systemic chemotherapy remains the most common first-line treatment, despite ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...